Option

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, January 22, 2021 - 9:04pm

The inducement stock options and RSUs have a grant date and vesting commencement date of January 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The inducement stock options and RSUs have a grant date and vesting commencement date of January 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2020 Long-Term Incentive Plan.
  • ARENA Pharmaceuticals is a team with a singular purpose deliver our important medicines to patients.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Bioasis Announces Stock Option Grant

Friday, January 22, 2021 - 2:19pm

GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC .

Key Points: 
  • GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC .
  • The options expire five years from the date of the grant, are subject to vesting and are governed by the terms of the companys stock option plan.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • Bioasis trades on the TSX Venture Exchange under the symbol BTI and on the OTCQB under the symbol BIOAF.

TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Friday, January 22, 2021 - 2:02pm

a) Description of the financial instrument, type of instrument, identification code

Key Points: 
  • a) Description of the financial instrument, type of instrument, identification code
    Amendment of an existing Forward Purchase with trade date 2021-01-11 UTC in respect of the maximum price.
  • Pursuant to the amended Forward Purchase, the notifying party acquires up to a total number of 66,422,880 Subscription Rights for TUI AG Ordinary Shares at a maximum price (excluding commission) of up to EUR 3.10 per Subscription Right.
  • The Subscription Rights will be acquired from the market by the counterparty in the time period until 22 January 2021 (subject to early termination) up to a fixed daily target number of Subscription Rights at a maximum daily price per Subscription Right (such number and price may be amended daily by the parties, subject to the total number and maximum price mentioned above) and will be delivered to the notifying party at the aggregate amount of all purchase prices at which they were acquired by the counterparty (plus commission) in one settlement.
  • The transaction is not linked to the exercise of a share option programme.

Crescent NV Enters Into a Financing Agreement With LDA Capital Limited

Friday, January 22, 2021 - 6:45am

Crescent (EURONEXT: OPTI; OTC: OPNVY) announces it has entered into a financing agreement with LDA Capital Limited (LDA).

Key Points: 
  • Crescent (EURONEXT: OPTI; OTC: OPNVY) announces it has entered into a financing agreement with LDA Capital Limited (LDA).
  • Crescent has committed to issue a minimum amount of EUR 5 million in shares to LDA Capital within 18 months.
  • This Capital Commitment will be released based on capital calls by Crescent in the form of put options which Crescent has the right to exercise at its own discretion.
  • The minimum subscription price of the new shares shall not be lower than EUR 0.03, unless otherwise agreed by LDA Capital and Crescent.

UrbanGold Appoints VP Corporate Development and Grants Stock Options

Thursday, January 21, 2021 - 10:12pm

Laval, Quebec--(Newsfile Corp. - January 21, 2021) - UrbanGold Minerals Inc. (TSXV: UGM) ("UrbanGold" or the "Company") is pleased to announce that it has appointed Robert J. Casaceli as Vice President Corporate Development, effective today.

Key Points: 
  • Laval, Quebec--(Newsfile Corp. - January 21, 2021) - UrbanGold Minerals Inc. (TSXV: UGM) ("UrbanGold" or the "Company") is pleased to announce that it has appointed Robert J. Casaceli as Vice President Corporate Development, effective today.
  • "On behalf of UrbanGold, I am very pleased to welcome Robert Casaceli as Vice President Corporate Development," commented Jens Hansen, interim President and Chief Executive Officer of the Company.
  • The Company's Board of Directors has authorized and approved, as of today, the granting of stock options (the "Options") for an aggregate of 1,450,000 common shares to the Directors, Officers and a consultant under its stock option plan.
  • UrbanGold does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Options Medical Weight Loss Park Ridge to Host Grand Opening in February

Thursday, January 21, 2021 - 3:00pm

Options Medical Weight Loss offers 5 different options for customers to achieve their weight loss goals.

Key Points: 
  • Options Medical Weight Loss offers 5 different options for customers to achieve their weight loss goals.
  • That is why we offer one on one weight loss counselors to be with you during your weight loss journey," said Will Barton, President/Co-Founder of Options Medical Weight Loss.
  • Options Medical Weight Loss Center is the premier medical weight loss facility offering services in Chicago, South Loop, Glenview, Naperville, Orland Park, Park Ridge, Gahanna, Dublin, the Valley, Chandler/Gilbert, and St. Petersburg.
  • We also understand that an individual's weight loss journey is not always an easy process, which is why we offer FDA approved appetite suppressants including Phentermine as well as other prescriptions used for weight loss, weekly one-on-one weight loss counseling, Lipotropic fat burners, B12 injections, HCG injections, Options Diet System, Options meals and snacks, Options supplements and more to help assist you during your customized weight loss program.

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Thursday, January 21, 2021 - 2:50am

In addition, CytomX has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public offering price, on the same terms and conditions.

Key Points: 
  • In addition, CytomX has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public offering price, on the same terms and conditions.
  • CytomX expects to use the net proceeds from this offering to further develop its proprietary Probody therapeutics pipeline and research.
  • CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital and other general corporate purposes.
  • J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Sandler are acting as joint bookrunning managers for the offering.

Bentley Systems Announces Launch of Private Offering of Convertible Senior Notes

Thursday, January 21, 2021 - 1:07am

Bentley also expects to grant the initial purchasers of the Notes a 13-day option to purchase up to an additional $75.0 million aggregate principal amount of Notes.

Key Points: 
  • Bentley also expects to grant the initial purchasers of the Notes a 13-day option to purchase up to an additional $75.0 million aggregate principal amount of Notes.
  • The Notes will be senior unsecured obligations of Bentley and will accrue interest payable semiannually in arrears.
  • The Notes will be convertible into cash, shares of Bentleys Class B common stock or a combination thereof at Bentleys election.
  • The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the offering.

Bit.com to Launch Industry's First BCH Options

Wednesday, January 20, 2021 - 1:00pm

BCH options trading will go live on 01 Feb 2021, following the launch of BCH perpetual swaps on 20 Jan 2021.

Key Points: 
  • BCH options trading will go live on 01 Feb 2021, following the launch of BCH perpetual swaps on 20 Jan 2021.
  • However, there has been no options market for BCH and the liquidity of the perpetual swaps also has room for improvement.
  • The launch of BCH derivatives by Bit.com enables miners to hedge against risks associated with BCH volatility, which helps make their operation more stable and efficient.
  • Being the first to launch the product will help Bit.com take a vantage point in this blue ocean market.

Aclaris Announces Pricing of Public Offering of Common Stock

Wednesday, January 20, 2021 - 1:45pm

WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.

Key Points: 
  • WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.
  • In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount.
  • The gross proceeds from the offering to Aclaris are expected to be approximately $96.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters option.
  • However, while Aclaris may elect to update these forward-looking statements at some point in the future, Aclaris specifically disclaims any obligation to do so.